News Releases

Date	Title and Summary	View
Oct 21, 2021	U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
Oct 21, 2021	Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2021
Oct 20, 2021	Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Oct 19, 2021	Johnson & Johnson Reports Q3 2021 Results
Oct 15, 2021	Janssen Receives Positive CHMP Opinion for RYBREVANT® (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy
Oct 15, 2021	Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Oct 15, 2021	OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health CanadaApproved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)
Oct 14, 2021	Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
Oct 13, 2021	Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
Oct 13, 2021	New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis